CClinicalTrials.gg
CompletedNCT03034980Updated Feb 27, 2018

Influence of Training Intensity in Coronary Artery Disease

An observational study in Coronary Artery Disease, sponsored by Hasselt University. Completed at 1 site in Belgium. Open to participants aged 25 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-02-27.

Sponsored by Hasselt University · Observational

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
343
Ages
25 Years to 90 Years
Sex
All
01

Study summary

Coronary artery disease (CAD) is associated with high mortality worldwide. Narrowing of the coronary arteries can cause an acute myocardial infarction. Patient with cardiac ischemia are often treated with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Following hospitalisation, the patients are offered to attend a classical rehabilitation program with moderate exercise intensity. Current exercise program for cardiac rehabilitation has proven to reduce cardiovascular risk factors 1. Is it possible to improve the exercise capacity and risk profile even more if the exercise program includes more vigorous training? The program starts one week after the cardiac incident (AMI, PCI or CABG) and takes 12 weeks to complete. Patients with heart failure and valvular disease are excluded. First ventilatory threshold (VT1) and second ventilatory threshold (VT2) are determined during cycloerometry. VT2 reflects aerobic-anaerobic transition and therefore the aerobic functional capacity2. Exercise load reached at VT2 is used to determine the training load during rehabilitation.

The research goal is to investigate the influence of training intensity on the exercise capacity and risk profile of CAD patients.

02

Conditions studied

03

In context

Coronary Artery Disease

5,596 studies on the registry are indexed under Coronary Artery Disease; 955 are open to participants now.

This study's planned enrollment of 343 is close to the median of 336 across 1,946 observational studies indexed under Coronary Artery Disease.

Browse Coronary Artery Disease studies →

Lead sponsor

Hasselt University is the lead sponsor of 195 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.

Inclusion criteria

  • Patients with acute myocardial infarction (AMI), who underwent a percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). The 12-week program must be completed.

Exclusion criteria

Exclusion Criteria:

  • Patients with heart failure (HFpEF and HFrEF with ejection fraction ≤40%) and valvular heart disease.
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
343 participants (estimated)
Patient registry
No

Groups and cohorts

  • Coronary Artery Disease (CAD) patients

    Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.

    Other: Training intensity (workload) during ergospirometry

Interventions

  • OtherTraining intensity (workload) during ergospirometry

    The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.

06

What researchers measure

Primary outcomes

  1. exercise capacity

    The primary endpoint is the relationship between the actual training load (W) and exercise capacity (VO2max) obtained at the end of the rehabilitation.

    Time frame: up to week 12

Secondary outcomes

  1. cardiovascular risk profile

    The secondary endpoint is the relationship between relative training load and the cardiovascular risk factors.

    Time frame: up to week 12

07

Study locations

1 site
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03034980
Lead sponsor
Hasselt University
Collaborators
Jessa Hospital
Responsible party
prof. dr. Paul Dendale (prof. dr., Hasselt University) — Principal investigator
First posted
Jan 27, 2017
Start date
Dec 20, 2016
Primary completion
Jul 1, 2017
Completion
Sep 15, 2017
Last update
Feb 27, 2018

Study contacts

Kaatje Goetschalckx, MD
principal investigator · Catholic University Leuven, Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion